BOSTON, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, is scheduled to present at the Cowen & Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 11:20 AM ET. A live audio webcast of the presentation will be available on Zafgen's website, www.zafgen.com under the Events and Presentations section of the Investor page.
About Zafgen, Inc.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesity therapeutics, including agents known to inhibit MetAP2 that had been found to drive unprecedented weight loss and metabolic improvements in mice. The company is located in Boston, MA.
CONTACT: Investor Relations Contact: Shauna Elkin (212) 850-5613 Shauna.Elkin@fticonsulting.comSource:Zafgen, Inc.